Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (DORIC Trial).

Trial Profile

Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (DORIC Trial).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cediranib (Primary) ; Gefitinib
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms DORIC
  • Most Recent Events

    • 03 Jul 2014 Planned End Date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
    • 03 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 30 Oct 2012 Accrual to date is 33% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top